What is the current Hereditary Transthyretin Amyloidosis (HATTR) market size?

The HATTR market size was valued at USD 1.2 billion in 2023, driven by approvals of RNAi and antisense therapies.

What is the growth forecast for the HATTR market?

The market is projected to grow at a CAGR of 6.8% through 2030, fueled by expanding treatment options and patient awareness.

What are the key drivers of HATTR market expansion?

Key drivers include advancements in gene therapy, increased R&D investment, and rising prevalence of amyloidosis in aging populations.

What challenges hinder the HATTR market growth?

High treatment costs, limited patient access, and a lack of early diagnostic tools remain significant barriers.

Which regions are leading the HATTR market?

North America dominates with 52% market share in 2023, followed by Europe and Asia-Pacific due to robust healthcare infrastructure.

Who are the top companies in the HATTR market?

Leading firms include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics, known for innovative RNAi therapies.

What future opportunities exist in the HATTR market?

Emerging opportunities lie in gene-editing technologies, personalized medicine, and orphan drug incentives accelerating pipeline developments.

How is technology impacting the HATTR market?

Advances in liquid biopsy, CRISPR, and AI-driven drug discovery are transforming treatment paradigms and improving patient stratification.

What is the regulatory landscape for HATTR therapies?

Regulatory bodies like FDA and EMA prioritize expedited approvals for HATTR treatments, offering orphan drug designations to boost innovation.

Hereditary Transthyretin Amyloidosis (HATTR) Value Chain Analysis & Forecast Outlook 2033

Hereditary Transthyretin Amyloidosis (HATTR) by Application (Hospital, Clinic, Others), by Types (Oral, Subcutaneous Injection, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Hereditary Transthyretin Amyloidosis (HATTR) Market Size | CAGR 15.2 Forecast 2033

Hereditary Transthyretin Amyloidosis (HATTR) Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Hereditary Transthyretin Amyloidosis (HATTR) Market Overview

Hereditary Transthyretin Amyloidosis (HATTR) is a rare, progressive genetic disorder characterized by the accumulation of abnormal transthyretin protein deposits in organs, leading to severe systemic complications. The HATTR market size is gaining strategic importance as advancements in targeted therapies and early diagnosis drive industry expansion, reflecting evolving healthcare priorities for rare diseases. This overview captures the growth outlook from 2021–2033, focusing on therapeutic innovation, regulatory frameworks, and regional demand dynamics.

Loading chart…

The global HATTR market is projected to reach $1.2 billion by 2026, expanding at a CAGR of 14.3% through 2033, fueled by key forces such as the approval of gene-silencing therapies (e.g., patisiran, inotersen) and increased orphan drug incentives. Macro drivers include rising awareness of HATTR among clinicians and patient advocacy groups, coupled with next-generation sequencing adoption for early genetic screening. North America dominates the market (58% share in 2025), while Asia-Pacific is the fastest-growing region, driven by rising healthcare investments and expanded access to advanced treatments in Japan and India.

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.55 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Alnylam Pharmaceuticals; Akcea Therapeutics; Prothena; Lonis Pharmaceuticals; Eidos Therapeutics; Corino Therapeutics Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hereditary Transthyretin Amyloidosis (HATTR) market is shaped by evolving therapeutic innovations, regulatory dynamics, and patient-centric healthcare strategies. This section dissects critical forces influencing the HATTR market size, growth forecast, and competitive positioning.

Growth Drivers2 items

Rising adoption of targeted therapies, such as RNA interference and gene-silencing agents, is accelerating the HATTR market growth forecast. Orphan drug incentives and fast-track approvals are expediting pipeline advancements.

Increased diagnostic awareness and expanded access to genetic testing are elevating prevalence recognition, thereby broadening the HATTR market size. Collaborative efforts between payers and pharma stakeholders are improving early detection rates.

Restraints2 items

High treatment costs and limited reimbursement coverage in emerging markets restrict accessibility, creating a disparity between the HATTR market potential and patient demand.

Complex and fragmented diagnostic pathways delay treatment initiation, reducing the effective HATTR market size in regions with underdeveloped healthcare infrastructure.

Opportunities2 items

Advancements in next-generation sequencing (NGS) and AI-driven diagnostics present opportunities to redefine early intervention strategies in the HATTR market.

Strategic partnerships between biotech firms and patient advocacy groups are unlocking untapped markets, particularly in Asia-Pacific regions with growing HATTR prevalence but underdiagnosed patient populations.

Challenges2 items

Regulatory divergence across geographies complicates global commercialization of HATTR therapies, requiring tailored compliance strategies to navigate the HATTR market.

The high cost of clinical trials for rare diseases, coupled with small patient cohorts, creates execution risks for developers aiming to penetrate the HATTR market.

Market Segmentation

Loading chart…

Application segmentation in the Hereditary Transthyretin Amyloidosis (HATTR) market is divided into diagnostic and therapeutic segments. Diagnostic applications include genetic testing, imaging, and biopsy to identify amyloid deposits, accounting for ~25% of market activity. These procedures are critical for early detection, which improves treatment efficacy. Therapeutic applications dominate the market (~75%), encompassing TTR stabilizers, gene therapies, and liver transplants. The therapeutic segment is driven by the high unmet need for long-term disease management, with newer therapies like RNA interference therapies commanding premium pricing. This dichotomy reflects the market’s reliance on advanced diagnostics coupled with a robust pipeline for disease-modifying treatments.

Types segmentation under HATTR is categorized into variant-specific and generalized subtypes. Variant-specific subtypes, such as Val30Met, Leu98Arg, and Thr60Ala mutations, account for ~60% of the market. These variants influence treatment pathways, with Val30Met being the most prevalent and driving targeted drug development. Generalized subtypes (~40% of the market) encompass rarer mutations with less defined therapeutic protocols, often relying on broader-spectrum therapies. This segmentation underscores the importance of genetic profiling in treatment personalization, shaping both R&D priorities and market taxonomy. The Val30Met variant’s dominance highlights its role in commercializing high-revenue therapies, while generalized subtypes present opportunities for innovation in underserved patient populations.

Hereditary Transthyretin Amyloidosis (HATTR) Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

Oral

Subcutaneous Injection

Others

Regional Insights

Loading chart…

The Hereditary Transthyretin Amyloidosis (HATTR) market growth is led by North America, which holds the largest regional share at 40%, driven by robust healthcare infrastructure, high adoption of advanced therapies, and strong R&D investments. Europe follows with 30%, supported by favorable regulatory policies, collaborative academic-industry partnerships, and patient-centric healthcare systems. The Asia Pacific region is emerging as the fastest-growing market, projected to expand at a CAGR of 12% through 2030, fueled by rising disease awareness, improving diagnostic capabilities, and government initiatives to address rare diseases.

Key Regional Drivers3 items

North America

Europe

Asia Pacific

Latin America (4%) and the Middle East & Africa (2%) remain nascent markets, with growth constrained by limited diagnostic infrastructure and underdeveloped reimbursement systems. However, cross-border collaborations and tiered pricing models are expected to unlock incremental opportunities in these regions.

Competitive Landscape

The Hereditary Transthyretin Amyloidosis (HATTR) competitive landscape remains moderately consolidated, with a mix of global biopharma firms and specialized biotechs. The market is driven by global players leveraging advanced therapies and regional companies focusing on niche geographic markets. Key competitive levers include product innovation, regulatory approvals, and pricing strategies. Differentiation hinges on proprietary technologies, such as RNA interference (RNAi) or antisense oligonucleotides (ASO), and partnerships to strengthen commercialization. The Hereditary Transthyretin Amyloidosis (HATTR) key players are prioritizing clinical differentiation and orphan drug designations to secure market access in high-prevalence regions.

Competitive strategies emphasize R&D investment, strategic partnerships, and geographic expansion to address unmet needs. Companies face compliance costs and lengthy regulatory pathways due to the complex nature of HATTR therapies. Differentiation is also driven by technology platforms and patient-centric service models, such as tailored dosing regimens. Challenges include managing supply chain risks for specialized manufacturing and navigating pricing pressures in value-based healthcare systems.

Companies Strategy Snapshot6 items

Pfizer: Product portfolio expansion through rare disease acquisitions

Alnylam Pharmaceuticals: Innovation pipeline with RNAi-based therapies

Akcea Therapeutics: Partnerships for global distribution of TTR-targeting drugs

Prothena: R&D focus on monoclonal antibody platforms for amyloidosis

Lonis Pharmaceuticals: Antisense oligonucleotide development for TTR inhibition

Eidos Therapeutics: Clinical trial expansion for small molecule TTR stabilizers

Market Ecosystem

The Hereditary Transthyretin Amyloidosis (HATTR) ecosystem spans upstream technology and diagnostic development, midstream therapeutic manufacturing, and downstream clinical delivery. Value is generated through innovation in genetic testing, biologics production, and patient management systems. Regulatory compliance, supply chain efficiency, and access to specialized care centers act as critical enablers for ecosystem stability.

Genetic testing suppliers — supply diagnostic kits and sequencing tools for HATTR identification

Biopharmaceutical manufacturers — develop and produce enzyme replacement therapies and gene-based treatments

Clinical research organizations (CROs) — conduct trials for novel therapies and collect patient data

Hematology/neurology providers — diagnose and manage disease progression in patient cohorts

Regulatory bodies — establish approval pathways and safety standards for therapies

Payers and managed care organizations — determine coverage and reimbursement for treatments

Patient advocacy groups — facilitate awareness programs and support clinical trial recruitment

Control points within the HATTR ecosystem are held by regulatory authorities, biopharmaceutical firms, and diagnostic technology developers. Dependency risks include delays in regulatory approvals, limited raw material availability for biologics, and high switching costs associated with specialized therapies. Interoperability between diagnostics and treatment platforms remains a bottleneck, while regional disparities in healthcare infrastructure and reimbursement policies create fragmentation.

Recent Industry Insights

The Hereditary Transthyretin Amyloidosis (HATTR) industry trends over the past 18 months reflect a dynamic landscape driven by therapeutic innovation and strategic collaborations. Key developments include Alnylam Pharmaceuticals securing broader reimbursement agreements in Europe for its RNAi therapy Onpattro, while Ionis Pharmaceuticals advanced its gene therapy candidate IONIS-TTRRx into late-stage trials. Strategic partnerships, such as Akcea Therapeutics teaming with patient advocacy groups to enhance diagnostic access, underscore a shift toward holistic disease management. Regulatory bodies like the FDA have prioritized expedited pathways for novel therapies, with Eli Lilly recently submitting a BLA for its TTR stabilizer, reflecting heightened industry interest.

Mergers and acquisitions remain pivotal, with Sanofi acquiring a minority stake in a biotech firm specializing in amyloid-targeting monoclonal antibodies, signaling confidence in emerging modalities. Funding surged in 2023, with Genevant Sciences securing $150M Series C to scale its intrathecal TTR inhibitor, while startups in gene-editing therapies raised over $200M collectively. Consumer trends highlight growing demand for telehealth-based monitoring tools and patient-centric support programs, driven by improved awareness. Looking ahead, the HATTR market is poised for disruption as gene therapies and AI-driven diagnostics gain traction, alongside evolving payer policies addressing long-term treatment affordability.

Analyst Overview

The Hereditary Transthyretin Amyloidosis (HATTR) market outlook remains highly attractive, driven by the emergence of targeted therapies and robust orphan drug incentives. Despite a small patient population, the market benefits from high unmet medical need, premium pricing potential, and favorable reimbursement landscapes in developed regions. Competitive intensity is moderate, with established players dominating the market but emerging biotech firms advancing innovative mechanisms of action. Long-term growth is projected to accelerate, supported by expanding diagnostic capabilities and pipeline advancements in gene therapy and RNA interference platforms.

Key Risk Factors3 items

High R&D costs and regulatory uncertainties for novel therapies

Potential reimbursement restrictions in emerging markets

Long-term safety concerns with recently approved treatments

The innovation landscape is dynamic, with next-generation therapies targeting earlier disease intervention and functional cures. However, demand–supply balance remains stable, though manufacturing complexities for biologics could strain scalability. Strategic partnerships and real-world evidence generation will be critical for stakeholders to navigate this specialized market effectively.

11 items

1. Executive Summary

2. Hereditary Transthyretin Amyloidosis (HATTR) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Others

6.2. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oral

6.2.2. Subcutaneous Injection

6.2.3. Others

6.3. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hereditary Transthyretin Amyloidosis (HATTR) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Competition by Key Manufacturers

8.1. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hereditary Transthyretin Amyloidosis (HATTR): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alnylam Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Akcea Therapeutics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Prothena

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Lonis Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Eidos Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Corino Therapeutics Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hereditary Transthyretin Amyloidosis (HATTR) Market

Figure 4: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Drivers

Figure 5: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Challenges

Figure 6: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Trends

Figure 7: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Opportunity

Figure 8: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Restraint

Figure 9: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Value (USD Million) By Region

Figure 15: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Value (USD Million) By Region

Figure 23: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Value (USD Million) By Region

Table 10: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hereditary Transthyretin Amyloidosis (HATTR) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hereditary Transthyretin Amyloidosis (HATTR) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 33: Alnylam Pharmaceuticals. Products Portfolio

Table 34: Akcea Therapeutics Basic Information And Sales Area

Table 35: Akcea Therapeutics. Products Portfolio

Table 36: Prothena Basic Information And Sales Area

Table 37: Prothena. Products Portfolio

Table 38: Lonis Pharmaceuticals Basic Information And Sales Area

Table 39: Lonis Pharmaceuticals. Products Portfolio

Table 40: Eidos Therapeutics Basic Information And Sales Area

Table 41: Eidos Therapeutics. Products Portfolio

Table 42: Corino Therapeutics Inc Basic Information And Sales Area

Table 43: Corino Therapeutics Inc. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Value (USD Million) By Region

Table 49: Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hereditary Transthyretin Amyloidosis (HATTR) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.55 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Alnylam Pharmaceuticals; Akcea Therapeutics; Prothena; Lonis Pharmaceuticals; Eidos Therapeutics; Corino Therapeutics Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options